These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
248 related articles for article (PubMed ID: 24979997)
21. Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis. Guerry MJ; Brogan P; Bruce IN; D'Cruz DP; Harper L; Luqmani R; Pusey CD; Salama AD; Scott DG; Savage CO; Watts RA; Jayne DR Rheumatology (Oxford); 2012 Apr; 51(4):634-43. PubMed ID: 21613248 [TBL] [Abstract][Full Text] [Related]
22. [ANCA-associated vasculitis]. Holle JU Z Rheumatol; 2013 Jun; 72(5):445-56. PubMed ID: 23743987 [TBL] [Abstract][Full Text] [Related]
23. [Use of rituximab in the induction of remission of severe, resistant and recurrent form of polyangiitis associated with c-ANCA antibodies - case report]. Brodowska-Kania D; Rymarz A; Saracyn M; Geisler P; Niemczyk S Pol Merkur Lekarski; 2015 Apr; 38(226):216-8. PubMed ID: 25938389 [TBL] [Abstract][Full Text] [Related]
24. Biologics for ANCA-associated vasculitis. Murgia G; Firinu D; Manconi PE; Del Giacco SR Inflamm Allergy Drug Targets; 2014; 13(4):275-87. PubMed ID: 24998311 [TBL] [Abstract][Full Text] [Related]
26. [Rituximab (MabThera): a new therapy for ANCA vasculitis]. von Frenckell C; Delanaye P Rev Med Liege; 2015 Feb; 70(2):92-100. PubMed ID: 26011994 [TBL] [Abstract][Full Text] [Related]
27. B-cell depleting agents for ANCA vasculitides: a new therapeutic approach. Gómez-Puerta JA; Quintana LF; Stone JH; Ramos-Casals M; Bosch X Autoimmun Rev; 2012 Jul; 11(9):646-52. PubMed ID: 22146313 [TBL] [Abstract][Full Text] [Related]
28. [Uptodate in the management and treatment of ANCA-associated vasculitis]. Belaconi IN; Toma CL; Bogdan MA Pneumologia; 2014; 63(2):78-80, 83-6. PubMed ID: 25241554 [TBL] [Abstract][Full Text] [Related]
31. Extending the indications for rituximab in ANCA-associated vasculitis. Jayne D N Engl J Med; 2014 Nov; 371(19):1839-40. PubMed ID: 25372093 [No Abstract] [Full Text] [Related]
32. S1. Rituximab for ANCA-associated vasculitis: the experience in the United States. Clain JM; Specks U Presse Med; 2013 Apr; 42(4 Pt 2):530-2. PubMed ID: 23477713 [No Abstract] [Full Text] [Related]
33. Rituximab or cyclophosphamide in ANCA-associated renal vasculitis. Nossent JC N Engl J Med; 2010 Nov; 363(21):2072; author reply 2073-4. PubMed ID: 21083400 [No Abstract] [Full Text] [Related]
34. [Treatment of ANCA-associated vasculitis ... 40 years later]. Arazzi M G Ital Nefrol; 2013; 30(5):. PubMed ID: 24941484 [No Abstract] [Full Text] [Related]
35. Is B-cell depletion first choice in antineutrophil cytoplasmic antibody-associated vasculitis? Kallenberg CG Curr Opin Rheumatol; 2014 May; 26(3):292-8. PubMed ID: 24646946 [TBL] [Abstract][Full Text] [Related]
36. Rituximab or azathioprine maintenance in ANCA-associated vasculitis. Chouchana L; Beaune P; Loriot MA N Engl J Med; 2015 Jan; 372(4):386. PubMed ID: 25607436 [No Abstract] [Full Text] [Related]
37. Rituximab or azathioprine maintenance in ANCA-associated vasculitis. Vandergheynst F N Engl J Med; 2015 Jan; 372(4):385-6. PubMed ID: 25607435 [No Abstract] [Full Text] [Related]
38. Rituximab or azathioprine maintenance in ANCA-associated vasculitis. Hebert LA; Alvarado A; Rovin B N Engl J Med; 2015 Jan; 372(4):385. PubMed ID: 25607434 [No Abstract] [Full Text] [Related]
39. Rituximab or azathioprine maintenance in ANCA-associated vasculitis. Pagnoux C; Guillevin L; ; N Engl J Med; 2015 Jan; 372(4):386-7. PubMed ID: 25607433 [No Abstract] [Full Text] [Related]
40. New horizons for treatment of ANCA-associated vasculitides. Guillevin L; Mahr A Rheumatology (Oxford); 2012 Apr; 51(4):583-4. PubMed ID: 21729933 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]